This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Ability to understand and the willingness to sign a written informed consent document and to comply with the study protocol procedures.
Age ≥18 years.
Diffuse large B-cell lymphoma, not otherwise specified (NOS)
T-cell/histiocyte-rich large B-cell lymphoma
Pregnancy, breast-feeding, or prisoner status.
Central nervous system involvement by the lymphoma.
Prior solid organ transplantation or allogeneic stem cell transplantation.
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products.
Brown University
Lead sponsor
Incyte Corporation
Collaborator
Genentech, Inc.
Collaborator
Natera, Inc.
Collaborator